The US Food and Drug Administration (FDA) has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for insertion in the right ventricle. This new 4.7 French (1.6mm) lead, which ...

A team of researchers from Sergio Arboleda University in Bogotá, Colombia, and the Georgia Institute of Technology in Atlanta utilized an electrophysiological computer model of the heart’s electrical ...

Defibrillation testing of implantable cardioverter–defibrillators (ICDs) does not improve outcomes compared with device implantation without testing and, therefore, “defibrillation testing during ...

Defibrillation testing is performed at implantable cardioverter-defibrillator (ICD) implantation to ensure adequate defibrillation efficacy and sensing of ventricular fibrillation (VF). 1, 2 This is ...

OBJECTIVETo determine the use of epinephrine (adrenaline) before defibrillation for treatment of in-hospital cardiac arrest due to a ventricular arrhythmia and examine its association with patient ...

Ventricular fibrillation is a lethal condition where the heartbeat becomes too disorganised to maintain proper circulation. It is treated with defibrillation, which applies an electric shock in an ...

Sequences of low-energy electrical pulses can effectively terminate ventricular fibrillation (VF) and avoid the side effects of conventional high-energy electrical defibrillation shocks, including ...

Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...

Traditional hospital factors -- such as case volume and academic status -- do not appear to predict whether patients with cardiac arrest at that facility are likely to experience delays in receiving ...

Researchers used an electrophysiological computer model of the heart's electrical circuits to examine the effect of the applied voltage field in multiple fibrillation-defibrillation scenarios. They ...